For example, CD22 responds to 2-hydroxypropyl-beta-cyclodextrin, which is in phase 2 and 3 clinical trials for Niemann–Pick disease, to reduce microglia-associated defects (Cougnoux et al. 2018), and antibodies directed against CD22 reduce microglial impairment in aging brains (Pluvinage et al. 2019). Here, CD22 is linked to Niemann-Pick disease.